Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 665-674

  Köck, Kathleen ^a   Ferslew, Brian C ^a   Netterberg, Ida ^a,c   Yang, Kyunghee ^a   Urban, Thomas J ^d   Swaan, Peter W ^e   Stewart, Paul W ^b   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT EXPORT PUMP; DRUG METABOLITE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PROTEIN INHIBITOR;

ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EMBRYO; HUMAN; HUMAN CELL; MEMBRANE VESICLE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RISK ASSESSMENT; RISK FACTOR; TOXIC HEPATITIS;

ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTASIS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEK293 CELLS; HUMANS; LIVER; LOGISTIC MODELS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TRANSFECTION;

EID: 84887978608     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054304     Document Type: Article

References (42)

1. AHFS Drug Information. (2012) American Society of Health-System Pharmacists, Bethesda, MD.
2. Akita H, Suzuki H, Hirohashi T, Takikawa H, and Sugiyama Y (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 19:34-41.
3. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen ZS, Grinberg A, Westphal H, and Klein-Szanto A, et al. (2005) Analysis of the in vivo functions of Mrp3. Mol Pharmacol 68:160-168. (Pubitemid 41002955)
4. Chai J, He Y, Cai SY, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, and Wu X, et al. (2012) Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 55:1485-1494.
5. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, et al. International Transporter Consortium. (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94(1):126-41.
6. Dawson S, Stahl S, Paul N, Barber J, and Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130-138.
7. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231. (Pubitemid 32382504)
8. Floyd JS, Barbehenn E, Lurie P, and Wolfe SM (2009) Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 18:1238-1243.
9. Ghibellini G, Leslie EM, Pollack GM, and Brouwer KLR (2008) Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 25:1851-1860.
10. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, and Bachmakov I, et al. (2008) Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8:42-52.
11. Hirano M, Maeda K, Hayashi H, Kusuhara H, and Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876-882. (Pubitemid 41043874)
12. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647-2658.
13. Jansen PL and Muller M (2000) Genetic cholestasis: lessons from the molecular physiology of bile formation. Can J Gastroenterol 14:233-238. (Pubitemid 30182427)
14. Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, De Jager-Krikken A, Kuipers F, and Stellaard F, et al. (1999) Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117:1370-1379.
15. Kaplowitz N and DeLeve LD (2007) Drug-Induced Liver Disease, 2nd ed, CRC Press, New York.
16. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H, Sinclair JF, and Sahi J (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220-228. (Pubitemid 37361901)
17. Kreiss C, Amin S, Nalesnik MA, Chopra K, and Shakil AO (2002) Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol 97:775-777. (Pubitemid 34245928)
18. Lammert C, Bjornsson E, Niklasson A, and Chalasani N (2010) Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51:615-620.
19. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, and Chalasani N (2008) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47:2003-2009. (Pubitemid 351945567)
20. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220. (Pubitemid 34441937)
21. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, and Schuetz JD (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 57:24-35. (Pubitemid 30033256)
22. Lee WM (2003) Acute liver failure in the United States. Semin Liver Dis 23:217-226.
23. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, and Rodriguez-González JF, et al.; Spanish Group for the Study of Drug-Induced Liver Disease (2009) Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 49:2001-2009.
24. Mayoral W, Lewis JH, and Zimmerman H (1999) Drug-induced liver disease. Curr Opin Gastroenterol 15:208-216. (Pubitemid 29257646)
25. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, and Boyer JL (2006) Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43:1013-1021. (Pubitemid 43724626)
26. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, and Hamadeh HK (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 118:485-500.
27. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT 2nd, Afshari CA, and Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci [published ahead of print].
28. Noé J, Stieger B, and Meier PJ (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659-1666. (Pubitemid 35231665)
29. Perez MJ and Briz O (2009) Bile-acid-induced cell injury and protection. World J Gastroenterol 15:1677-1689.
30. Puls F, Agne C, Klein F, Koch M, Rifai K, Manns MP, Borlak J, and Kreipe HH (2011) Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch 458:709-716.
31. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:374-384. (Pubitemid 36919858)
32. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, and Scheper RJ (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82:193-201. (Pubitemid 34160456)
33. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430. (Pubitemid 30067515)
34. Stricker BHC (1992) Drug-Induced Hepatic Injury, 2nd ed., Elsevier, Amsterdam, New York.
35. Teng S and Piquette-Miller M (2007) Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151:367-376. (Pubitemid 46842676)
36. Wagner M, Zollner G, and Trauner M (2009) New molecular insights into the mechanisms of cholestasis. J Hepatol 51:565-580.
37. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, and Borst P (2003a) Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 371:361-367. (Pubitemid 36547618)
38. Zelcer N, Saeki T, Bot I, Kuil A, and Borst P (2003b) Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J 369:23-30. (Pubitemid 36174121)
39. Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400-46407.
40. Zelcer N, van deWetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, and van der Valk M, et al. (2006) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44:768-775.
41. Zeng H, Liu G, Rea PA, and Kruh GD (2000) Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60:4779-4784.
42. Zimmermann HJ (1999) Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins; Philadelphia